Investigator Initiated Trials- Medullary Thyroid Cancer
Lilly Oncology is dedicated to delivering innovative treatment approaches with the goal of improving the outcomes of people living with cancer. We are driven to accelerate the pace and progress of cancer care by developing a broad portfolio of therapies, including those tailored to unique patients and those that modulate the immune system. Lilly’s commitment to improving the length and quality of people’s lives is achieved through its internal drug development programs and its support of Investigator Initiated Research.
Research Area of Current Focus In Scope for Clinical:
- Combination studies of selpercatinib with other agents whenever mechanistically appropriate or clinically appropriate
- Studies evaluating the role of additional/other RET alterations (mutations, amplifications, over-expression) impacting cancer
- Studies in medullary thyroid cancer that is not RET-mutant
- Studies of selpercatinib to treat emerging oncogenic RET alterations as an acquired resistance mechanism to prior treatments
Research Area Out of Scope for Clinical:
- Concepts that may pose a potential safety risk
- Concepts that compete against ongoing or future Lilly-sponsored studies
- Studies evaluating RET-fusion positive lung cancer in adjuvant setting
PIRA™ suggested Proposal
PIRA™ proposals are AI generated and are not reviewed or endorsed by the sponsoring company.